AHR and prostate carcinoma: siRNA-mediated knockdown of AhR in LNCaP-EnzR cells led to considerable downregulation of CCND1, CREB3L2, NFKB1, CREB5, PPP2R3A, EDN1, HSPG2, REL, and ANAPC13 (Fig. 5g), strongly suggesting that AhR in advanced prostate cancer tumours is involved mainly in cancer cell growth and progression, in contrast to its function in early-stage androgen-dependent prostate cancer in response to ADT.